{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:21:41Z","timestamp":1787008901147,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jaad.2024.11.043","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T16:52:04Z","timestamp":1733158324000},"page":"741-752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Evaluating cancer risk in a large cohort of 25,008 patients with vitiligo: Insights from a comprehensive cohort population-based study"],"prefix":"10.1016","volume":"92","author":[{"given":"Yochai","family":"Schonmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naama T.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tali","family":"Czarnowicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9988","key":"10.1016\/j.jaad.2024.11.043_bib1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.043_bib2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1159\/000506103","article-title":"Vitiligo: a review","volume":"236","author":"Bergqvist","year":"2020","journal-title":"Dermatology"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.043_bib3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2174\/1573396316666201210125858","article-title":"Vitiligo: an updated narrative review","volume":"17","author":"Leung","year":"2021","journal-title":"Curr Pediatr Rev"},{"issue":"9","key":"10.1016\/j.jaad.2024.11.043_bib4","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/jid.2009.32","article-title":"Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients","volume":"129","author":"van den Boorn","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.043_bib5","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.abd.2021.09.008","article-title":"Update on the pathogenesis of vitiligo","volume":"97","author":"Marchioro","year":"2022","journal-title":"Anais Brasileiros De Dermatologia"},{"key":"10.1016\/j.jaad.2024.11.043_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1072837","article-title":"Beyond skin white spots: Vitiligo and associated comorbidities","volume":"10","author":"Hu","year":"2023","journal-title":"Front Med"},{"issue":"5","key":"10.1016\/j.jaad.2024.11.043_bib7","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jid.2022.10.021","article-title":"Comorbidities in patients with vitiligo: a systematic review and meta-analysis","volume":"143","author":"Lee","year":"2023","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.043_bib8","first-page":"1119","article-title":"Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer","volume":"32","author":"Franks","year":"2012","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.043_bib9","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaad.2014.07.050","article-title":"Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo","volume":"71","author":"Paradisi","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.043_bib10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/bjd.12111","article-title":"Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners","volume":"168","author":"Teulings","year":"2013","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.043_bib11","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jaad.2008.09.033","article-title":"Incidence of nonmelanoma skin cancer in a cohort of patients with vitiligo","volume":"60","author":"Hexsel","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2024.11.043_bib12","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.jid.2023.04.013","article-title":"Risk of melanoma and nonmelanoma skin cancer in people with vitiligo: United Kingdom population-based cohort study","volume":"143","author":"Ferguson","year":"2023","journal-title":"J Invest Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2024.11.043_bib13","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.3390\/ijerph15091847","article-title":"Cancer risks in vitiligo patients: a nationwide population-based study in Taiwan","volume":"15","author":"Li","year":"2018","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.043_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-99786-9","article-title":"Reduced risk of skin cancer and internal malignancies in vitiligo patients: a retrospective population-based cohort study in Taiwan","volume":"11","author":"Weng","year":"2021","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.jaad.2024.11.043_bib15","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1200\/JCO.18.01223","article-title":"Markedly reduced risk of internal malignancies in patients with vitiligo: a nationwide population-based cohort study","volume":"37","author":"Bae","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2024.11.043_bib16","article-title":"Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study","volume":"35","author":"Beydon","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.043_bib17","first-page":"404","article-title":"Prevalence of selected chronic diseases in Israel","volume":"3","author":"Rennert","year":"2001","journal-title":"Isr Med Assoc J"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.043_bib18","first-page":"23","article-title":"An assessment of the completeness and timeliness of the Israel national cancer registry","volume":"23","author":"Moore","year":"2021","journal-title":"Isr Med Assoc J"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.043_bib19","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/00420989650011627","article-title":"Living together apart: residential segregation in mixed Arab-Jewish cities in Israel","volume":"33","author":"Falah","year":"1996","journal-title":"Urban Stud"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.043_bib21","first-page":"240","article-title":"New insights on oxidative stress in cancer","volume":"12","author":"Visconti","year":"2009","journal-title":"Curr Opin Drug Discov Devel"},{"issue":"11","key":"10.1016\/j.jaad.2024.11.043_bib22","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.freeradbiomed.2010.09.006","article-title":"Oxidative stress, inflammation, and cancer: how are they linked?","volume":"49","author":"Reuter","year":"2010","journal-title":"Free Radic Biol Med"},{"issue":"7","key":"10.1016\/j.jaad.2024.11.043_bib23","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/jid.2011.463","article-title":"A mouse model of vitiligo with focused epidermal depigmentation requires IFN-\u03b3 for autoreactive CD8+ T-cell accumulation in the skin","volume":"132","author":"Harris","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.043_bib24","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/bjd.14416","article-title":"Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo","volume":"174","author":"Wang","year":"2016","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.043_bib25","article-title":"Role of CXCL10 in the progression of in situ to invasive carcinoma of the breast","volume":"11","author":"Kim","year":"2021","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.043_bib26","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3892\/ol.2011.300","article-title":"The emerging role of CXCL10 in cancer (Review)","volume":"2","author":"Liu","year":"2011","journal-title":"Oncol Lett"},{"issue":"7","key":"10.1016\/j.jaad.2024.11.043_bib27","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.autrev.2010.02.011","article-title":"Vitamin D and autoimmune rheumatologic disorders","volume":"9","author":"Pelajo","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.043_bib28","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jaad.2009.11.024","article-title":"A pilot study assessing the role of 25 hydroxy vitamin D levels in patients with vitiligo vulgaris","volume":"62","author":"Silverberg","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.043_bib29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/carcin\/bgm240","article-title":"Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer--results of a large case-control study","volume":"29","author":"Abbas","year":"2008","journal-title":"Carcinogenesis"},{"issue":"11","key":"10.1016\/j.jaad.2024.11.043_bib30","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/jnci\/djn152","article-title":"Serum vitamin D concentration and prostate cancer risk: a nested case-control study","volume":"100","author":"Ahn","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.043_bib31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/09546634.2020.1735615","article-title":"Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis","volume":"33","author":"Phan","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2024.11.043_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.790125","article-title":"Janus kinase inhibitors in the treatment of vitiligo: a review","volume":"12","author":"Qi","year":"2021","journal-title":"Front Immunol"},{"issue":"16","key":"10.1016\/j.jaad.2024.11.043_bib33","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two phase 3, randomized, controlled trials of Ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jaad.2024.11.043_bib34","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1111\/jdv.19162","article-title":"Topical ruxolitinib: a new treatment for vitiligo","volume":"37","author":"Tavoletti","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.043_bib35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jdin.2020.03.004","article-title":"Risk of skin cancer in patients with vitiligo in Denmark: a nationwide cohort study","volume":"1","author":"Jorgensen","year":"2020","journal-title":"JAAD Int"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.043_bib36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.det.2016.11.003","article-title":"Skin cancer risk (nonmelanoma skin cancers\/melanoma) in vitiligo patients","volume":"35","author":"Rodrigues","year":"2017","journal-title":"Dermatol Clin"},{"issue":"9","key":"10.1016\/j.jaad.2024.11.043_bib37","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.jid.2018.03.1511","article-title":"Inverse relationship between vitiligo-related genes and skin cancer risk","volume":"138","author":"Wu","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2024.11.043_bib38","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/ng.3680","article-title":"Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants","volume":"48","author":"Jin","year":"2016","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.043_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001439","article-title":"Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy","volume":"8","author":"Cubas","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.jaad.2024.11.043_bib40","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/bjd.18247","article-title":"The incidence and survival of melanoma and nonmelanoma skin cancer in patients with vitiligo: a nationwide population-based matched cohort study in Korea","volume":"182","author":"Kim","year":"2020","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.043_bib41","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1464-410X.1989.tb05199.x","article-title":"Squamous cell carcinoma of\u00a0the bladder presenting as vitiligo","volume":"63","author":"Banerjee","year":"1989","journal-title":"Br J Urol"},{"issue":"3","key":"10.1016\/j.jaad.2024.11.043_bib42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/pcan.2009.7","article-title":"Vitamin D and prostate cancer risk: a review of the epidemiological literature","volume":"12","author":"Gupta","year":"2009","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.jaad.2024.11.043_bib43","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s40257-017-0323-8","article-title":"Vitamin D and the skin: an update for dermatologists","volume":"19","author":"Kechichian","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2024.11.043_bib44","article-title":"Vitamin D deficiency in patients with vitiligo: a cross-sectional study from Basrah, Iraq","volume":"13","author":"Mahmmod","year":"2021","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.jaad.2024.11.043_bib45","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1684\/ejd.2018.3449","article-title":"Vitiligo and thyroid disease: a systematic review and meta-analysis","volume":"28","author":"Fan","year":"2018","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2024.11.043_bib46","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3389\/fendo.2017.00290","article-title":"Vitiligo and autoimmune thyroid disorders","volume":"8","author":"Baldini","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.043_bib47","article-title":"Thyroid autoimmunity in vitiligo: a case-control study","volume":"15","author":"Prashant","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jaad.2024.11.043_bib48","article-title":"Cancer risk in Hashimoto's thyroiditis: a systematic review and meta-analysis","volume":"13","author":"Hu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.jaad.2024.11.043_bib49","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.mce.2009.10.003","article-title":"Thyroid cancer\u00a0and inflammation","volume":"321","author":"Guarino","year":"2010","journal-title":"Mol Cell Endocrinol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224032845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224032845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T04:11:49Z","timestamp":1742357509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962224032845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0190962224032845"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2024.11.043","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating cancer risk in a large cohort of 25,008 patients with vitiligo: Insights from a comprehensive cohort population-based study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2024.11.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}